|Mol. mass||146.3 kDa|
|(what is this?)|
This drug was developed by ImClone Systems Inc. under the name IMC-A12.
It is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis.
- Statement On A Nonproprietary Name Adopted By The Usan Council - Cixutumumab American Medical Association.
- McKian, KP; Haluska, P (2009). "Cixutumumab". Expert Opinion on Investigational Drugs 18 (7): 1025–33. doi:10.1517/13543780903055049. PMC 2939377. PMID 19548856.
-  National Cancer InstituteTemplate:Http://www.cancer.gov/drugdictionary/?CdrID=561575
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|